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Tuesday, August 2, 2022
As the COVID-19 pandemic continues to evolve, we are seeing other emerging public health threats/emergencies and we continue to address
ongoing/emerging disaster issues, the Center for Disaster Medicine has been and will continue to be a source of reliable information, education and
models for mitigation, preparedness, response, and recovery. As such we are expanding this informational document to address the broader areas
addressed by the center while retaining critical COVID19 information. You will notice we have updated the name to CDM Info Brief. As the pace of new
information and changes occur, we will evaluate the current once per week to determine if this information should be provided on a more frequent basis.

                                                                                                                       
David Markenson, M.D., M.B.A.
Director
Center for Disaster Medicine

COVID-19 Statistics
Total Cases

Total Deaths

Total Vaccine Doses
Admin.

Worldwide

578,284,562

6,402,795

11,973,568,249

United States

91,472,958

1,030,499

599,865,455

New Jersey

2,599,211

34,270

17,925,211

New York

5,833,909

70,321

40,706,749

Connecticut

854,934

11,102

7,958,343

     Information as of 8/2/22 at 0700 EDT. Source: https://coronavirus.jhu.edu/map.html

United States COVID-19 Case Map / GIS

Center for Disaster Medicine Updates
Coordinating and overseeing COVID-19 screenings at NYMC campus.
Continue to partner with local organizations such as Westchester Department of Emergency Services and Westchester Medical
Center to ensure ongoing collaboration with all public safety agencies.
Coordinating volunteers to support local public health response to COVID-19.
Conducting research and analysis of current events and COVID-19 response to identify strengths and areas for improvement in
other regions.
Updating and developing new programs to provide enhanced education on public health emergencies including pandemics.
Exploring course development opportunities in infection prevention and control for frontline responders in the hospital and in the
field.
Serving as a source of information for COVID-19 related concerns or questions regarding public health, emergency medical service
(EMS), public safety and healthcare response.
Local networking and pandemic response analysis for New York’s tri-state area, using first-person experiences to highlight current
trends.  
On July 21, 2022, CDM staff provided STOP THE BLEED workshop to staff and students of the NYMC community. This life-saving
training is ongoing on a monthly basis so that everyone has an opportunity to raise their level of awareness and knowledge.

                                      

The White House
The official website of the White House will deliver updated information as the country grapples
with converging crises. This will include actions to control current public health threats, provide
economic relief, tackle climate change, and advance racial equity and civil rights, as well as
immediate actions to reform our immigration system and restore America’s standing in the world.
This website will provide all information in one central location.
President Biden named FEMA’s Robert Fenton as the White House National Monkeypox
Response Coordinator and Dr. Demetre Daskalakis as the White House National
Monkeypox Response Deputy Coordinator. Fenton and Daskalakis will lead the
Administration’s strategy and operations to combat the current monkeypox outbreak,
including equitably increasing the availability of tests, vaccinations and treatments. Robert
Fenton currently serves as Regional Administrator for FEMA Region 9 in the American
West, with nearly 50 million people in his area of responsibility. One of the nation’s most

experienced and effective emergency management leaders, Robert Fenton has twice
served as Acting Administrator of FEMA and led multiple challenging prevention, response
and recovery operations throughout his long and distinguished career, including for natural
disasters, disease outbreaks, and complex humanitarian operations. Demetre Daskalakis, a
leading public health expert, is currently Director of the CDC Division of HIV Prevention.
Widely known as a national expert on health issues affecting the LGBGQIA+ communities,
his clinical practice has focused on providing care for the underserved LGBTQIA+
communities. He previously oversaw management of infectious diseases for the New York
City Department of Health and Mental Hygiene, one of the largest departments in the nation
– including in serving as incident commander for the City’s COVID-19 response. Fenton and
Daskalakis combined have more than four decades of experience in Federal emergency
response and public health leadership, including overseeing the operations and
implementation of key components of the Biden Administration’s response to the COVID-19
pandemic, and leading local and Federal public health emergency efforts such as infectious
disease control and HIV prevention. Both played critical roles in making COVID vaccines
more accessible for underserved communities and closing the equity gap in adult
vaccination rates, through the implementation and execution of FEMA mass vaccination
sites in some of the country’s most underserved communities, and working with trusted
members of local communities to build vaccine confidence. For more on this release,
plesase visit https://www.whitehouse.gov/briefing-room/statementsreleases/2022/08/02/president-biden-announces-team-to-lead-monkeypox-response/
https://www.whitehouse.gov

COVID-19 Website
On March 30, 2022, Biden Administration Launched COVID.gov, a New One-Stop Shop Website
for Vaccines, Tests, Treatments, Masks, and the Latest COVID-19 Information- a new website was
launched in an effort to consolidate information for consumers.
https://www.whitehouse.gov/briefing-room/statements-releases/2022/03/30/fact-sheet-bidenadministration-launches-covid-gov-a-new-one-stop-shop-website-for-vaccines-tests-treatmentsmasks-and-the-latest-covid-19-information/

Health and Human Services (HHS)
The U.S. Department of Health and Human Services (HHS), in collaboration with the U.S.
Department of Defense (DOD), announced an agreement to purchase 66 million doses of
Moderna’s bivalent COVID-19 vaccine booster candidate for potential use in the fall and
winter. This contract announcement follows a recommendation by the FDA last month that
vaccine manufacturers update their existing COVID-19 vaccines to create a bivalent booster
that can target BA.4 and BA.5 Omicron subvariants. This purchase is in addition to the 105
million bivalent COVID-19 vaccine booster doses the U.S. government purchased recently
from Pfizer for potential use later this year, pending FDA authorization and a
recommendation by CDC. Pending those FDA and CDC actions, HHS would receive the first
deliveries of the Moderna and Pfizer vaccine booster doses in early fall. “We must stay
vigilant in our fight against COVID-19 and continue to expand Americans’ access to the best
vaccines and treatments,” said HHS Secretary Xavier Becerra. “As we look to the fall and
winter, we’re doing just that—ensuring Americans have the tools they need to stay safe and
help keep our nation moving forward.” “We look forward to receiving these new variantspecific vaccines and working with state and local healthcare partners to make the vaccines
available for free in communities around the country this fall,” said HHS Assistant Secretary
Dawn O’Connell who leads the Administration for Strategic Preparedness and Response
(ASPR). Existing COVID-19 vaccines remain the single most important tool in preventing
serious illness, hospitalization, and death, and given the current threat that BA.5 Omicron
subvariant poses, it is essential that Americans stay up to date with their COVID-19
vaccinations. At the same time, the virus is dynamic, and the Administration continues to act
aggressively to ensure that Americans have access to the latest, most protective vaccines
as quickly as they become available. https://www.hhs.gov/about/news/2022/07/29/bidenharris-administration-secures-66-million-doses-modernas-variant-specific-covid-19-vaccinebooster-for-potential-use-in-fall-winter-2022.html

For the latest COVID-19 information from HHS
https://www.hhs.gov/about/news/coronavirus/index.html

National Institutes of Health (NIH)
View the latest COVID-19 information from NIH.
https://www.nih.gov/coronavirus

Centers for Disease Control and Prevention (CDC)        
CDC provides updated information about the variants in the United States- The
emerging variants CDC is closely monitoring have mutations in the virus genome that
alter the characteristics and cause the virus to act differently in ways that are

significant to public health (e.g., causes more severe disease, spreads more easily
between humans, requires different treatments, changes the effectiveness of current
vaccines). It’s important to understand that genetic mutations are expected, and
some variants can spread and become predominant while others subside.
https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant-cases.html
CDC provides daily data tracker which has maps and charts tracking cases, deaths,
and trends of COVID-19 in the United States- updated daily by 8 p.m. ET.
https://covid.cdc.gov/covid-data-tracker/#datatracker-home
For the latest CDC information
https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/index.html

United States Food and Drug Administration (FDA)
The FDA updated the FAQs on Testing for SARS-CoV-2 to note that no tests
remain on the commercial manufacturer serology test notification list described
in the FDA’s Policy for Coronavirus Disease-2019 Tests. All tests previously
on the commercial manufacturer serology test notification list have either been
issued an Emergency Use Authorization or should no longer be distributed,
marketed, or offered.
The U.S. Food and Drug Administration is providing an update on its
multipronged response to monkeypox in the United States, including its efforts
in the areas of diagnostics, vaccines and therapeutics. The agency has also
established a dedicated website to provide important information about the
FDA’s ongoing regulatory activities related to monkeypox along with frequently
asked questions. The FDA will provide updates as developments occur and
will continue to work with federal public health partners and industry to ensure
timely access to all available medical countermeasures. “The FDA has been
closely tracking reports of monkeypox transmissions in the United States with
our federal public health partners and coordinating preparedness efforts
accordingly,” said FDA Commissioner Robert M. Califf, M.D. “We understand
that while we are still living with COVID-19, an emerging disease may leave
people feeling concerned and uncertain, but it’s important to note that we
already have medical products in place, specifically an FDA-approved vaccine
for the prevention of monkeypox disease and an FDA-cleared diagnostic test.
The FDA is using the full breadth of its authorities to make additional
diagnostics and treatments available. We will continue to collaborate with our
partners across all sectors to expand accessibility to countermeasures and
bolster the tools in our arsenal as appropriate.” The monkeypox virus is part of
the same family of viruses as variola virus, the virus that causes smallpox (a
virus that has been eradicated globally). Both monkeypox and smallpox fall
into the category of “orthopoxviruses.” Monkeypox is generally not fatal and
typically resolves on its own without treatment. The current outbreak in the
U.S. usually presents as a rash on the body, face or genital area. Although
there is a very low risk of dying, there have been reported complications
including severe pain, at times requiring hospital admission.
Diagnostics
Since the first case of monkeypox in the U.S. was detected, the
FDA has been working with commercial laboratories and
manufacturers to make monkeypox tests more readily available
to consumers who need them. The Centers for Disease Control
and Prevention (CDC) has an FDA-cleared non-variola
orthopoxvirus test that can detect monkeypox by a swab from a
monkeypox lesion (rash or growth). At this time, this is the only
FDA-cleared test. The FDA is not aware of clinical data
supporting the use of other sample types, such as blood or
saliva, for monkeypox virus testing. In July 2022, the FDA
issued a safety communication advising people to use swab
samples taken directly from a lesion when testing for the
monkeypox virus.
The FDA-cleared monkeypox test is being offered by the CDC
and throughout many laboratories that include the CDC’s public
health Laboratory Response Network. In addition, federal public
health authorities have worked with industry to make the test
available through five large commercial laboratories. The agency
is working closely with the CDC to increase production of its
FDA-cleared test and the FDA has cleared the use of additional
reagents and instruments to increase the throughput of the CDC
test.
The FDA will continue to work with the diagnostic community to
augment access to accurate testing to support the response.
Vaccines
In 2019, the FDA approved the JYNNEOS Vaccine for the
prevention of smallpox and monkeypox in adults 18 years of age
and older determined to be at high risk of infection. JYNNEOS is
the only vaccine approved for the prevention of monkeypox in
the United States. Although clinical trials and data are limited
because of the small number of cases until now, the
immunological response to vaccine administration is consistent
with effective prevention of the disease.
Following the emerging public health crisis closely, the FDA was
aware that there were close to 800,000 doses of this vaccine
pending release this fall following approval of additional
manufacturing capabilities at one of the plants where the vaccine
is made. With this in mind, the agency worked with HHS
partners and expedited the submission of the required

application for the company’s manufacturing changes in order to
make these doses available to those in need. After accelerating
the timeline for an inspection of the plant from fall to earlier this
month, the FDA has finished its evaluation of the required
information to validate product quality and has determined that
the vaccine meets its quality standards.
On July 26, the agency approved a supplement to the biologics
license for the JYNNEOS Vaccine, to allow for additional
manufacturing capabilities at the facility. Given the emerging
public health need, the FDA previously facilitated the shipment
of manufactured doses to the U.S. so that they would be ready
to be distributed once the manufacturing changes were
approved. With the supplement approval, those manufactured
doses may now be further distributed and administered.
Additional doses manufactured at this plant can help address the
need for this vaccine moving forward.
Therapeutics
There is no FDA-approved or authorized medicine for the
treatment of monkeypox disease; however, TPOXX
(tecovirimat), an antiviral medication, is being made available
through the CDC under an FDA authority called Expanded
Access or “compassionate use.” The FDA continues to work with
the CDC to streamline their Expanded Access Program for
monkeypox to facilitate access.
There are currently no human data demonstrating the efficacy of
TPOXX for the treatment of monkeypox, or the safety and
pharmacokinetic profile (which helps us understand what the
human body does to a drug). Although expanded access
program is available, conducting randomized, controlled trials to
assess TPOXX’s safety and efficacy in humans with monkeypox
infections is essential.
The FDA has more information on TPOXX’s approval for
smallpox under the “Animal Rule” regulations on its monkeypox
webpage.
COVID-19 testing updates:
As of today, 438 tests and sample collection devices are authorized by
the FDA under emergency use authorizations (EUAs). These include
301 molecular tests and sample collection devices, 85 antibody and
other immune response tests, 51 antigen tests, and 1 diagnostic breath
test. There are 78 molecular authorizations and 1 antibody
authorization that can be used with home-collected samples. There is 1
EUA for a molecular prescription at-home test, 2 EUAs for antigen
prescription at-home tests, 19 EUAs for antigen over-the-counter (OTC)
at-home tests, and 3 for molecular OTC at-home tests.
The FDA has authorized 31 antigen tests and 8 molecular tests for
serial screening programs. The FDA has also authorized 1062 revisions
to EUA authorizations.
For the latest overall FDA information about COVID-19.
https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-andemerging-threats/coronavirus-disease-2019-covid-19

Center for Medicare and Medicaid Services (CMS)
View the latest information from CMS
https://www.cms.gov/About-CMS/Agency-Information/Emergency/EPRO/CurrentEmergencies/Current-Emergencies-page

Vaccines
CDC created this section regarding COVID-19 vaccinations in the United StatesCDC provides overall US COVID-19 Vaccine, deliveries and administration, maps,
charts, and data updated daily by 8 PM. This section represents all vaccine partners
including jurisdictional partner clinics, retail pharmacies, long-term care facilities,
Federal Emergency Management Agency and Health Resources and Services
Administration partner sites, and federal entity facilities.
https://covid.cdc.gov/covid-data-tracker/#vaccinations
The CDC has established a new website dedicated to the monkeypox virus
and 2022 U.S. outbreak. For more information, please visit
https://www.cdc.gov/poxvirus/monkeypox/index.html
The NYS DOH COVID-19 Vaccine Tracker Dashboard will update New Yorkers on
the distribution of the vaccine including the number of doses received by the state, a
breakdown of first or second doses, and the number of persons vaccinated with the
first and second doses in each region.
https://covid19vaccine.health.ny.gov/covid-19-vaccine-tracker
CDC created this section regarding the Johnson & Johnson’s Janssen vaccine to
provide updated relevant information including side effects and safety data, clinical

trials demographic statistics, and information on how the vaccine works.
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html
CDC created this section regarding the Moderna vaccine to provide updated relevant
information including side effects and safety data, clinical trials demographic
statistics, and information on how the vaccine works.
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/differentvaccines/Moderna.html
CDC created this section regarding the Pfizer BioNTech vaccine to provide updated
relevant information including side effects and safety data, clinical trials demographic
statistics, and information on how the vaccine works. As of October 16, 2021, the fully
FDA approved Pfizer vaccine will now be known as COMIRNATY for ages 16 and
older.
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/PfizerBioNTech.html
HHS created this section to provide the latest information about COVID-19 vaccines.
https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html
For NYC DOHMH updated guidance regarding COVID-19 vaccine
https://www1.nyc.gov/site/doh/covid/covid-19-vaccines.page
The Vaccine Finder is a one-stop site for New Yorkers to find their nearest COVID-19
vaccination location. The Vaccine Finder can also provide New Yorkers with
information to schedule vaccination appointments.
https://vaccinefinder.nyc.gov/

Educational Institution Information
Higher Education
The Pennsylvania State System of Higher Education
recently merged six of its public universities into two multicampus
institutions as part of an ongoing effort to maintain the system as a
driver of economic development and social mobility in the state. State
officials rewarded those efforts by approving PASSHE’s largest budget
increase ever. But amid this significant reorganization, a quieter, yet still
noteworthy, change also occurred. PASSHE sold its Dixon University
Center, the downtown Harrisburg building and grounds that formerly
housed the Office of the Chancellor. The sale reduced operating
expenses and generated an estimated annual savings of $2 million,
according to Kevin Hensil, a PASSHE spokesperson. The sale also
provided the university system an opportunity to allow the office’s 27
employees to work remotely on a permanent basis at a time when
colleges and universities are bleeding employees and looking for ways
to retain workers feeling battered by the pandemic and burned out from
heavy workloads. By being more flexible with remote work policies, the
system’s leaders are also reacting to post-pandemic workplace
pressures to innovate with the goal of optimizing employee productivity
and job satisfaction.
https://www.insidehighered.com/news/2022/07/29/building-sale-remotework-helped-pa-system-redesign
K-12
District leaders combined classes, bumped pay for substitute teachers,
asked teachers to take on more duties, and had central staff lead
classes during the 2021-22 school year as school systems continued to
recover from COVID-19-related impacts, according to a study by the
RAND Corp. The study found 90 percent of school districts changed
operations in one or more of their schools last school year and that
more than three-quarters of districts have added instructional and noninstructional staff compared to pre-pandemic levels. RAND surveyed a
random sample of 291 district and charter network leaders between
February 28, 2022, and April 10, 2022, for its fifth American School
District Panel Survey. The study said that although it is not clear why
districts choose certain operational changes over others, differences in
access to federal COVID-19 relief funds likely played a role in the ability
to increase pay and hiring to address understaffing.
https://www.k12dive.com/news/districts-shuffle-operations-in-responseto-covid-19/628411/
Despite a new COVID-19 variant that has led to another surge in cases,
mask mandates are continuing to loosen in school districts getting
ready to open for the new school year. A new wave of cases tied to
omicron subvariant BA.5 is expected to go on for the beginning of the

2022-23 school year, Mara Aspinall, a professor of practice at Arizona
State University’s College of Health Solutions and COVID-19 testing
advisor to the Rockefeller Foundation, told K-12 Dive last week.
Overall, districts upholding mask mandates into the new school year
appear to be in the minority. As of Monday, six of the top 500 districts
— or 1.2 percent — are requiring masks, according to data tracking
company Burbio. By comparison, 369 of 500 districts (73.8 percent)
required masks in October of 2021, Burbio found.
https://www.k12dive.com/news/school-mask-mandates-continue-toloosen/628527/

Clinical Trials
To view the latest information on clinical trials regarding COVID-19
https://www.clinicaltrials.gov/ct2/results?
recrs=&cond=Covid19&term=&cntry=&state=&city=&dist=

American Red Cross
https://www.redcrossblood.org/donate-blood/dlp/plasma-donations-from-recoveredcovid-19-patients.html

State Updates

New York

Statement by Governor Hochul: "I am grateful to President Biden and other Administration officials for their help in
securing an additional 110,000 monkeypox vaccine doses - approximately 80,000 to New York City and 30,000 to
the rest of New York State - which will be delivered over the next four to six weeks and allow us to continue to
respond to this troubling outbreak. This builds on the more than 60,000 monkeypox doses that New York City and
New York State have received to date due to our ongoing coordination with the federal government. "With more
than one-quarter of all cases in the U.S., New Yorkers, and especially our LGBTQ+ community, remain among the
hardest-hit. We will continue to advocate to the federal government for our fair share of vaccines based on the
disease burden impacting New York." "My team and I have been working around the clock to confront
the monkeypox outbreak and keep New Yorkers safe, and we will continue our ongoing efforts to secure more
vaccines, expand testing capacity, and educate the public on how to identify symptoms and protect themselves."
https://www.governor.ny.gov/news/statement-governor-kathy-hochul-110000-additional-monkeypox-vaccine-dosesnew-york-state-and
Governor Kathy Hochul issued an Executive Order declaring a State Disaster Emergency in response to the
ongoing monkeypox outbreak. The Executive Order enables the state to respond more swiftly to the outbreak and
allows health care professionals to take additional steps that will help get more New Yorkers vaccinated. "After
reviewing the latest data on the monkeypox outbreak in New York State, I am declaring a
State Disaster Emergency to strengthen our aggressive ongoing efforts to confront this
outbreak," Governor Hochul said. "More than one in four monkeypox cases in this country are in New York State,
and we need to utilize every tool in our arsenal as we respond. It's especially important to recognize the ways in
which this outbreak is currently having a disproportionate impact on certain at-risk groups. That's why my team and
I are working around the clock to secure more vaccines, expand testing capacity and responsibly educate the
public on how to stay safe during this outbreak." The Executive Order specifically extends the pool of eligible
individuals who can administer monkeypox vaccines, including EMS personnel, pharmacists and midwives;
allows physicians and certified nurse practitioners to issue non patient specific standing orders for vaccines; and
requires providers to send vaccine data to the New York State Department of
Health. https://www.governor.ny.gov/news/governor-hochul-declares-state-disaster-emergency-response-ongoingmonkeypox-outbreak

New York State Department of Health (DOH)
For a list of COVID-19 positive cases by county in New York Statehttps://covid19tracker.health.ny.gov/views/NYS-COVID19-Tracker/NYSDOHCOVID-19Tracker-Map?
%3Aembed=yes&%3Atoolbar=no&%3Atabs=n
NYS DOH has created a dynamic COVID-19 Tracker which provides COVID-19 information regarding testing, cases,
percentages, and fatalities across New York State. It also breaks down cases by county.
https://covid19tracker.health.ny.gov/views/NYS-COVID19-Tracker/NYSDOHCOVID-19Tracker-Map?
%3Aembed=yes&%3Atoolbar=no&%3Atabs=n

For the latest COVID-19 information from NYS DOH
https://coronavirus.health.ny.gov/home

New Jersey
Governor Phil Murphy and New Jersey Department of Health Commissioner Judith Persichilli announced two additional vaccination sites for
monkeypox in Camden and Bergen counties. These sites have been added for residents without a confirmed exposure who believe they may have
been exposed or are at high risk for having been exposed to the virus, the New Jersey Department of Health (NJDOH) announced today.
https://www.nj.gov/governor/news/news/562022/approved/20220728b.shtml

Local Updates
New York Blood Center (NYBC)
For the latest updated NYBC information about COVID-19:
https://nybc.org/covid-19/

New York City (NYC) Department of Health and Mental Hygiene (DOHMH)
New York City is currently the epicenter of the monkeypox outbreak in the United States. For the latest information including cases, symptoms, testing
and vaccine information regarding monkeypox in New York City, please visit
https://www1.nyc.gov/site/doh/health/health-topics/monkeypox.page
NYC DOHMH launched a new COVID-19 variants data page. The data on this page show how variants of the virus that causes COVID-19 are
spreading in NYC. Variants are versions of the virus with certain sets of mutations. Some variants may result in a COVID-19 infection that is easier to
spread, more severe or able to avoid antibodies from vaccines or previous infections.
https://www1.nyc.gov/site/doh/covid/covid-19-data-variants.page
For NYC DOHMH updated COVID-19 data page
https://www1.nyc.gov/site/doh/covid/covid-19-data.page
As of July 18, 2022, the NYC DOHMH is re-evaluating its COVID-19 Alert level system. For the current COVID-19 Alert level in New York City and
guidelines, please visit
https://www1.nyc.gov/site/doh/covid/covid-19-alert-levels.page

Westchester County Department of Health
For the latest breakdown of positive cases in Westchester County as of July 31, 2022
https://wcgis.maps.arcgis.com/apps/dashboards/280339d96db14efd9cc304dba0f3a71d
For the latest COVID-19 information in Westchester including vaccines for children.
https://health.westchestergov.com/2019-novel-coronavirus

Putnam County Department of Health
Breakdown of positive cases by towns in Putnam County as of July 29, 2022
https://www.putnamcountyny.com/covid19/

For the latest COVID-19 information
https://www.putnamcountyny.com/health/coronavirus/

Dutchess County Department of Health
Breakdown of positive cases in Dutchess County as of July 29, 2022
https://www.dutchessny.gov/Departments/DBCH/covid-19-dashboard.htm
For the latest COVID-19 information:
https://www.dutchessny.gov/Departments/DBCH/2019-Novel-Coronavirus.htm

Orange County Department of Health
Updated COVID-19 dashboard for Orange County, NY as of August 1, 2022
https://ocnygis.maps.arcgis.com/apps/dashboards/21de1fb5ce0c480f95dc0cf2b8b83b71
For the latest COVID-19 information
https://www.orangecountygov.com/1906/2019-Novel-Coronavirus-Information

Rockland County Department of Health
Review Rockland County’s dashboard with the latest COVID-19 information regarding cases as of August 1, 2022
https://www.arcgis.com/apps/dashboards/d074e0336e81449393a76d1768ceb096
For the latest COVID-19 information
https://rocklandgov.com/departments/health/coronavirus-covid-19/

Healthcare
For the latest COVID-19 information for healthcare facilities from the Greater New York Hospital Association that covers hospitals in the tri-state area.
https://www.gnyha.org/

   
                                   Center for Disaster Medicine Media
Faculty News:
Cómo Prepararse Para Emergencias Con Stop The Bleed
Univision Nueva York
7/30/2022
https://www.univision.com/local/nueva-york-wxtv/contigo/como-prepararse-para-emergencias-con-stop-the-bleed-video
George W. Contreras, M.E.P., M.P.H., M.S., CEM, FACEM, assistant director of the Center for Disaster Medicine and assistant professor in the
Institute of Public Health

Every effort is made to provide accurate and complete information in this newsletter. However, New York Medical College cannot guarantee that there will be no
errors. NYMC makes no claims, promises or guarantees about the accuracy, completeness, or adequacy of the contents of the newsletters or the articles linked herein

and further expressly disclaims liability for errors and omissions in the contents of this newsletter.
This newsletter is for informational purposes only; it does not constitute medical advice. Always seek the advice of your physician or other qualified health provider
with any questions you may have regarding a medical condition.

New York Medical College
Center for Disaster Medicine
7 Dana Road Suite 511
Valhalla, New York 10595
914-594-1750

https://www.nymc.edu/center-for-disaster-medicine/

If you wish to unsubscribe from this list, please click here:
NYMC ListServ unsubscribe

If you wish to unsubscribe from this list, please click here:
NYMC ListServ unsubscribe

